$5.3 Billion Investment: Eli Lilly is investing an additional $5.3 billion in its manufacturing plant in Lebanon, Indiana, to increase the production of its popular weight loss drug, Zepbound, and diabetes treatment, Mounjaro.
Expansion of Manufacturing Capacity: The investment aims to enhance the production of tirzepatide, the active ingredient in both Zepbound and Mounjaro, as well as other medicines in the company's pipeline.
Meeting Surging Demand: The demand for these treatments has outstripped supply over the past year, leading to shortages in the U.S. market, prompting Eli Lilly to invest substantially to amplify its manufacturing capabilities.
Total Investment: With this new commitment, Eli Lilly's total investment at the Lebanon site will reach $9 billion, making it the pharmaceutical giant's most significant manufacturing investment in its nearly 150-year history.
Job Creation: The plant is projected to employ 900 individuals, including engineers, scientists, operating personnel, and lab technicians, when the site reaches full capacity.
Manufacturing Timeline: The Lebanon site is expected to commence manufacturing medicines by the end of 2026, with operations scaling up through 2028.
Global Manufacturing Efforts: Since 2020, Eli Lilly has allocated over $18 billion for building, expanding, and purchasing manufacturing plants in the U.S. and Europe.
Government Support: The company is receiving government support, including economic incentives and infrastructure development, for its manufacturing expansion.